← Back to patent-cliff list
NBI-1070770
Tier C — Watch / tradeNBI-1070770
Takeda Pharmaceutical Company Limited
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NMDAR2B
Indications (approved)：Major depressive disorder
Regional status
US
Phase II
2024-03-20
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NBI-1070770?
Approved indications include: Major depressive disorder.
When does the NBI-1070770 patent expire?
No public expiry year is available for NBI-1070770 yet; this page updates once verified.
How do I get a quote for NBI-1070770 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01